PURPOSE: To assess the safety and effectiveness of transarterial chemoembolization (TACE) of @entity1 who have @entity157 ( @entity157 ) with central bile duct invasion. MATERIALS AND METHODS: The institutional review board approved this retrospective study and waived informed consent. Fifty-three @entity1 , initially treated with TACE for @entity157 with central bile duct invasion from January 1999 to September 2012, were included. Clinical, laboratory, and survival data were reviewed. Complications and hospitalization length were evaluated using  the    (2) test, Fisher's exact test, and logistic regression analysis. Survival was analyzed using the Kaplan-Meier method with log-rank test and  Cox proportional hazard model. RESULTS: Seven @entity1 experienced TACE-related major complications (severe @entity887 in 3, non-fatal @entity295 in 3, and secondary @entity298 in 1). The overall major complication rate was 13.2  %, but there were no permanent adverse sequelae or @entity204 within 30  days. Serum total @entity648 >= 3.0  mg/dL was the only significant risk factor for long hospitalization [hazard ratio (HR)  =  4.341, p  =  .022]. The median survival was 12.2  months. Extrahepatic @entity3 (HR  =  6.145, p  <  .001), international normalized ratio (PT-INR) >= 1.20 (HR  =  4.564, p  <  .001), vascular invasion (HR  =  3.484, p  =  .001), and intermediate @entity5 enhancement (HR  =  2.417, p  =  .019) were significantly associated with shorter survival. CONCLUSION: TACE can be a safe and effective treatment for @entity1 who have @entity157 with central bile duct invasion. In particular, long-term survival can be expected if @entity1 have strongly enhancing @entity5 without poor prognostic factors such as extrahepatic @entity3 , PT-INR prolongation, and vascular invasion.

Transarterial Chemoembolization for XXXX with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin'] @entity887 :: ('MESH:D004617', 'Disease') :: ['post-embolization syndrome'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCCs', 'hepatocellular carcinomas'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity298 :: ('MESH:D010538', 'Disease') :: ['bacterial peritonitis']
@entity157 :: (MESH:D006528,Disease) :: ['Hepatocellular Carcinomas']
